US 12,031,134 B2
KLF11 siRNA for treatment of diabetes and obesity
Seungil Ro, Reno, NV (US)
Assigned to Nevada Research & Innovation Corporation, Reno, NV (US)
Filed by NEVADA RESEARCH & INNOVATION CORPORATION, Reno, NV (US)
Filed on Aug. 12, 2021, as Appl. No. 17/401,200.
Claims priority of provisional application 63/065,242, filed on Aug. 13, 2020.
Prior Publication US 2022/0049254 A1, Feb. 17, 2022
Int. Cl. C12N 15/113 (2010.01); A61K 31/713 (2006.01); A61P 3/10 (2006.01)
CPC C12N 15/113 (2013.01) [A61K 31/713 (2013.01); A61P 3/10 (2018.01)] 2 Claims
OG exemplary drawing
 
1. A method of treating type-2 diabetes in a subject in need thereof, comprising administering to the subject an effective amount of an inhibitor of Kruppel-like factor 11 (KLF11) signaling, thereby treating type-2 diabetes; wherein the inhibitor is an siRNA encoded by a nucleotide sequence selected from the group consisting of SEQ ID NOs: 7 and 8.